On January 3, 2018, InMed Pharmaceuticals Inc. (DB:MWG2) closed the transaction. The company has issued 13,428,571 units for gross proceeds of CAD 9,400,000. The transaction was oversubscribed. The company has raised $1,633,700 (CAD 2,045,359.726) in funding from two investors pursuant to Regulation D. The company has paid the finder’s fee of CAD 397,527 and issued 446,646 warrants. The company has paid $67,722 (CAD 84,786.58956) to Canaccord Genuity Corp. Each finder warrant shall be exercisable in whole or in part at an exercise price of CAD 1.25 for a period of 18 months expiring on July 3, 2019.